selenomethylselenocysteine has been researched along with cyclin d1 in 1 studies
| Studies (selenomethylselenocysteine) | Trials (selenomethylselenocysteine) | Recent Studies (post-2010) (selenomethylselenocysteine) | Studies (cyclin d1) | Trials (cyclin d1) | Recent Studies (post-2010) (cyclin d1) |
|---|---|---|---|---|---|
| 202 | 6 | 107 | 10,885 | 70 | 5,157 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belame, A; Burow, ME; Carrier, L; Li, Z; Rowan, BG; Salvo, VA; Thiyagarajah, A | 1 |
1 other study(ies) available for selenomethylselenocysteine and cyclin d1
| Article | Year |
|---|---|
Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Division; Cyclin D1; Cysteine; Drug Synergism; Estradiol; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Organoselenium Compounds; Random Allocation; Receptors, Progesterone; Selenocysteine; Specific Pathogen-Free Organisms; Tamoxifen; Xenograft Model Antitumor Assays | 2009 |